GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
T

TheraCryf TCF.L · GBp

Health Care · LSE · 🇬🇧 United Kingdom

Compare

0.17p

0.00%

Close of 9 Nov 2026, in pence

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

TheraCryf — daily TCF

No embeddable chart for this listing. TradingView's free widgets do not cover this exchange, and an unsupported symbol would render an error panel rather than a chart.

View TheraCryf on TradingView ↗
Market value
£3.7m
Last close × shares
Volume
54.7k
Shares, 9 Nov 2026

About TheraCryf

Its shares trade on LSE under the ticker TCF.L. It has been listed since 21 October 2015. In the fiscal year to 31 March 2024, it reported revenue of £396,000 and a net loss of £3.1m. At that date it held total assets of £3.1m and shareholders' equity of £2.3m.

Evgen Pharma Plc is a clinical stage drug development company, which engages in the development of pharmaceutical products and focus on cancer and neurological disease. The company is headquartered in Wilmslow, Cheshire. The company went IPO on 2015-10-21. The firm operates through the segment of development of pharmaceutical products all within the United Kingdom. Its pipeline is based on its Sulforadex technology and includes various synthetic, stabilized analogues of the naturally occurring compound sulforaphane. Its pipeline includes SFX-01: breast cancer; SFX-01: subarachnoid hemorrhage, and other programs. The objective of SFX-01 therapy is to reduce the number of cancer stem cells (CSCs) proliferating in tumors treated with anti-hormonal agents and prolong the duration of response. The objective of SFX-01 therapy (co-administered with standard-of-care nimodipine) is to reduce the vasospasm and incidence of delayed cerebral ischemia in the days following the hemorrhage. The company has a preclinical SFX-01 program in multiple sclerosis and a clinical interest in prostate cancer.

Figures and description from our data supplier, not checked against the company's own report.

More about TheraCryf →

Latest on TheraCryf

Our reporting

We have not reported on TheraCryf yet.

Next results

17 Dec 2026

Due on 17 Dec 2026.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is TheraCryf's ticker?

TheraCryf trades as TCF.L on LSE, under ISIN GB00BSVYN304.

What was TheraCryf's last closing price?

0.17p on 9 Nov 2026. The figure is in GBp and is never converted.

When does TheraCryf next report results?

Results are expected on 17 Dec 2026, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.